Private company

Metacrine, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company currently focused on discovering and developing differentiated therapies for patients with gastrointestinal, or GI, diseases. Our most advanced program, MET642, targets the farnesoid X receptor, or FXR, which is central to modulating GI and liver diseases.”44 It is headquartered in San Diego, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address4225 Executive Square, Suite 600, San Diego, Ca 920372
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34-$61.1M in 2021+104% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$30.0M-$30.0M20192020: -$36.7M-$36.7M2020+22%2021: -$61.1M-$61.1M2021+66%
Net income34-$62.2M in 2021+115% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$28.9M-$28.9M20192020: -$37.3M-$37.3M2020+29%2021: -$62.2M-$62.2M2021+67%
Fiscal year20182019202020212022
Research and development$26.0M3$26.8M4$45.5M4
Operating expenses$61.1M4
Operating income-$30.0M3-$36.7M4-$61.1M4
Interest$347.0K3$1.0M4$1.2M4
Income before tax-$62.2M4
Income tax$03$04$04
Net income-$28.9M3-$37.3M4-$62.2M4

Compare Metacrine, Inc. with another company

Corporate structure

Metacrine, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Metacrine, Inc.

  • TANG CAPITAL PARTNERS LP Filed SC 13G/A on Metacrine, Inc., latest Feb 14, 2023 (2 filings since Dec 19, 2022)
  • BML Investment Partners, L.P. Filed SC 13G/A on Metacrine, Inc., latest Feb 8, 2023 (4 filings since Feb 18, 2022)
  • venBio Global Strategic Fund, L.P. Filed SC 13G/A on Metacrine, Inc., latest Feb 14, 2022
  • Franklin Templeton Investments Filed SC 13G/A on Metacrine, Inc., latest Feb 4, 2022
  • New Enterprise Associates 16, L.P. Filed SC 13D/A on Metacrine, Inc., latest Jan 5, 2022
  • Metacrine, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Metacrine, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.7M4 Dec 31, 2021$1.6M4 Dec 31, 2020+0.5%
Accumulated depreciation$1.3M4 Dec 31, 2021$1.0M4 Dec 31, 2020+29.2%
Property and equipment, net$347.0K4 Dec 31, 2021$634.0K4 Dec 31, 2020−45.3%
Operating-lease assets (leased space)$902.0K4 Dec 31, 2021$1.6M4 Dec 31, 2020−42.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$48.9M4 Dec 31, 2021$24.4M4 Dec 31, 2020+100.5%
Marketable securities, current$27.5M4 Dec 31, 2021$71.8M4 Dec 31, 2020−61.7%
Debt securities available for sale$27.5M4 Dec 31, 2021$71.8M4 Dec 31, 2020−61.7%

Leadership

Who has led Metacrine, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Preston Klassen2020–2023

President

  1. Preston Klassen2020–2023

Chief financial officer

  1. Trisha Millican2020–2021
2025
Board members and other officers (13)

Timeline

  1. Mar 24, 20238-K Change to shareholders' rights; Executive or director change; Shareholder vote22
  2. Mar 23, 20238-K Executive or director change23
  3. Mar 15, 20238-K Entered a material agreement; Completed an acquisition or sale24
  4. Mar 3, 20238-K Listing notice or transfer25
  5. Feb 9, 20238-K Entered a material agreement; Debt or obligation accelerated26
  6. Feb 3, 20238-K Executive or director change27
  7. Feb 1, 20238-K Listing notice or transfer28
  8. Jan 24, 20238-K Executive or director change; Other events29
  9. Dec 23, 20228-K Ended a material agreement; Shareholder vote; Other events30
  10. Nov 14, 20228-K Results of operations31
  11. Oct 11, 20228-K Other events32
  12. Sep 6, 20228-K Entered a material agreement; Other events33
  13. Sep 15, 2020New chief executive Preston Klassen becomes CEO8

Calendar

When it reported results

  1. Nov 14, 2022Reported quarterly or annual results31
  2. Aug 9, 2022Reported quarterly or annual results34
  3. May 12, 2022Reported quarterly or annual results35
  4. Mar 30, 2022Reported quarterly or annual results36
  5. Feb 11, 2022Reported quarterly or annual results37
  6. Nov 12, 2021Reported quarterly or annual results38

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

91 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 29 major events, 30 insider forms, 9 large holders, 18 other. The latest 20:

  1. Mar 24, 20234 FORM 4 SUBMISSION EDGAR
  2. Mar 24, 202315-12G EDGAR
  3. Mar 24, 20238-K EDGAR
  4. Mar 23, 2023S-8 POS EDGAR
  5. Mar 23, 2023S-8 POS EDGAR
  6. Mar 23, 20238-K EDGAR
  7. Mar 15, 20238-K EDGAR
  8. Mar 7, 2023EFFECT EDGAR
  9. Mar 3, 2023POS AM EDGAR
  10. Mar 3, 20238-K EDGAR
  11. Feb 14, 2023SC 13G/A AMENDMENT NO. 1 EDGAR
  12. Feb 13, 2023DEF 14A EDGAR
  13. Feb 9, 20238-K EDGAR
  14. Feb 8, 2023SC 13G/A NONE EDGAR
  15. Feb 3, 20238-K EDGAR
  16. Feb 1, 20238-K EDGAR
  17. Jan 27, 20234 FORM 4 SUBMISSION EDGAR
  18. Jan 27, 20234 FORM 4 SUBMISSION EDGAR
  19. Jan 24, 2023PRE 14A EDGAR
  20. Jan 24, 20238-K EDGAR

The 91 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

34 open-market trades by officers, directors and large owners since October 2021: 11 buys and 23 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 26, 2023York MichaelChief Business OfficerSale107,054$0.41$43.9KForm 4
Jan 26, 2023Klassen PrestonDirectorSale380,605$0.41$156.0KForm 4
Dec 21, 2022Leonard Braden Michael10% ownerBuy120,099$0.40$48.0KForm 4
Dec 20, 2022Leonard Braden Michael10% ownerBuy50,122$0.38$19.0KForm 4
Dec 19, 2022Leonard Braden Michael10% ownerBuy101,384$0.40$40.6KForm 4
Nov 9, 2022Leonard Braden Michael10% ownerBuy39,816$0.39$15.5KForm 4
Nov 8, 2022Leonard Braden Michael10% ownerBuy500$0.40$200Form 4
Nov 7, 2022Leonard Braden Michael10% ownerBuy123,954$0.42$52.1KForm 4
Oct 28, 2022Leonard Braden Michael10% ownerBuy45,022$0.40$18.0KForm 4
Oct 27, 2022Leonard Braden Michael10% ownerBuy767,507$0.39$299.3KForm 4
Oct 26, 2022Leonard Braden Michael10% ownerBuy588,533$0.35$206.0KForm 4
Oct 25, 2022Leonard Braden Michael10% ownerBuy499,279$0.35$174.7KForm 4
Oct 24, 2022Leonard Braden Michael10% ownerBuy174,354$0.34$59.3KForm 4
Apr 19, 2022Klassen PrestonDirectorSale44,748$0.50$22.4KForm 4
Dec 22, 2021Walker Paul Edward10% ownerSale459,700$0.97$444.3KForm 4
Dec 22, 2021Sonsini Peter W.10% ownerSale459,700$0.97$444.3KForm 4
Dec 22, 2021SANDELL SCOTT D10% ownerSale459,700$0.97$444.3KForm 4
Dec 22, 2021Makhzoumi Mohamad10% ownerSale459,700$0.97$444.3KForm 4
Dec 22, 2021Florence Anthony A. Jr.10% ownerSale459,700$0.97$444.3KForm 4
Dec 22, 2021Chang Carmen10% ownerSale459,700$0.97$444.3KForm 4

All 34 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Metacrine, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMetacrine, Inc.1
  • CIK0001634379
  • Employer ID (EIN)47-22973841
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address4225 Executive Square, Suite 600, San Diego, CA 920371
  • Phone858-369-78001
  • Shares outstanding42,569,515 as of Nov 9, 20227
  • Public float$75.8M as of Jun 30, 20214
  • On EDGAR sinceApr 13, 20151
  • Filings212 in all: 4 (65), 8-K (38), 3 (30), SC 13G (8), 10-Q (7), 425 (6), CORRESP (6), SC 13G/A (6)1
    All 33 form types

    UPLOAD (5), D (3), DEF 14A (3), DEFA14A (3), DRS/A (3), EFFECT (3), 10-K (2), D/A (2), DRSLTR (2), S-1/A (2), S-8 (2), S-8 POS (2), SC 13D (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), POS AM (1), PRE 14A (1), S-1 (1), S-3 (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2022
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Feb 13, 2023
    Latest 8-K (8-K) Mar 24, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44